Condition: Contact With or Exposure to Human Immunodeficiency Virus · Sponsor: Oswaldo Cruz Foundation
The goal of this study is to learn how well long-acting lenacapavir works to prevent human immunodeficiency virus (HIV) infection in people at higher risk of getting HIV in Brazil. The study will also learn about safety, continued use over time, and whether people prefer this option compared to daily oral pre- exposure prophylaxis (PrEP). The main questions it aims to answer are: How many participants get HIV while using long-acting lenacapavir? How safe is long-acting lenacapavir in real-world health services? How many participants continue using their chosen prevention method over time? What factors help or make it harder for participants to stay on prevention? Researchers will compare two HIV prevention options to understand how they work in routine care: Long-acting lenacapavir, given as an injection under the skin every 6 months, Daily oral pre-exposure prophylaxis (PrEP), taken as a pill containing tenofovir disoproxil fumarate and emtricitabine, Participants will choose the prevention option they prefer after receiving counseling. This is not a randomized study. Researchers will follow participants for up to 2 years. Participants will: Receive either an injection every 6 months or take a daily pill, Visit the clinic regularly for HIV testing and health checkups, Receive testing and treatment for sexually transmitted infections, Answer questions about their health, medication use, and experiences, Receive prevention counseling and condoms. This study will help health s…
This description comes directly from the study's public registry record.
Beatriz Grinsztejn, PhD · +55 2138659128 · gbeatriz@ini.fiocruz.br
Valdiléa Veloso, PhD · valdilea.veloso@ini.fiocruz.br
Always discuss trial participation with your own doctor first.
| Fundação de Medicina Tropical Heitor Vieira Dourado | Manaus, Amazonas, Brazil | Recruiting |
| CEDAP - Centro Especializado em Diagnóstico, Assistência e Pesquisa | Salvador, Estado de Bahia, Brazil | Recruiting |
| Hospital Geral de Nova Iguaçu | Nova Iguaçu, Rio de Janeiro, Brazil | Recruiting |
| Instituto Nacional de Infectologia Evandro Chagas | Rio de Janeiro, Rio de Janeiro, Brazil | Recruiting |
| CTA/Policlínica Centro | Florianópolis, Santa Catarina, Brazil | Recruiting |
| Centro de Referência em IST/Aids de Campinas (SMS/PMC) | Campinas, São Paulo, Brazil | Recruiting |
| Coordenadoria de IST/Aids da Cidade de São Paulo | São Paulo, São Paulo, Brazil | Recruiting |
| Centro de Referência e Treinamento em DST/Aids de São Paulo | São Paulo, São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07497594